Author

Myrtle Davis Millin

Observed name: MYRTLE DAVIS MILLIN

Institution: National Cancer Institute

Observed institutions: National Institutes of Health, National Cancer Institute

OpenAlex ID: A5064398802

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

2010 · Shivanni Kummar, Helen X. Chen, et al. · Nature Reviews Drug Discovery · 249

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

2019 · Taekyu Lee, Plamen P. Christov, et al. · Journal of Medicinal Chemistry · 73

Analyses of the combination of 6-MP and dasatinib in cell culture

2013 · GURMEET KAUR, HOLGER BEHRSING, et al. · International Journal of Oncology · 6

BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness.

2018 · Apurva K. Srivastava, Jeevan P Govindharajulu, et al. · Journal of Clinical Oncology · 3

Abstract 1303: Characterization of the metabolite profile for batracylin and N-acetylbatracylin in rat and human models of invitro and in vivo metabolism: Elucidation of pathways that might contribute to batracylin toxicity

2011 · Matthew M. Ames, Joel M. Reid, et al. · Cancer Research

Works count: 5

Citation count: 331

H-index: 3

I10-index: 2